Novel Rx
2 years ago
Low dose IL-2 works in Primary Sjogrens Syndr (pSS)? RCT 60 pSS pts rx w/ PBO vs LD-IL-2; latter lower ESSDAI @wk 24 (67% vs 27%; P=.004) & less Sxs (dryness,fatigue) @wk12 and expansion of TREGs & CD24highCD27+ B cells. https://t.co/39U6WX7ceM https://t.co/i56XDSvGXs
2 years ago
Exciting time to be doing research in GCA! Over half a dozen ongoing RCTs
Challenging to recruit enough patients given (1) competing trials (2) reticence to join a trial when tocilizumab (standard of care) is available
#ACR22 #Vasculitis22 @RheumNow https://t.co/mJm69gH4N9
Rheumatoid arthritis treatment has come leaps and bounds in recent decades. Gone are the days of gold injections, chemical synovectomies, and physician-mandated bedrest (heaven forbid). Though the…
The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent…
As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. There are three areas that always draw my attention each conference and…
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease which can be managed with both pharmacological and non-pharmacological options. The joint ASAS-EULAR…
Poster Hall